Clemson, United States
Aptus Bioreactors is a biotechnology and health care startup based in the United States, founded in 2013. The company's slogan "Regenerating Tissues, for Life" encapsulates its core mission - providing cardiovascular equipment and consulting services to develop and test living tissue replacements and other medical devices. Their groundbreaking technologies aim to revolutionize the treatment of heart valve disease and other cardiovascular conditions.
Aptus Bioreactors' innovative approach involves utilizing a patient's own stem cells to create patient-specific, living heart valves and blood vessels that not only grow and regenerate but also promise a life-long, personalized, and maintenance-free solution. This approach has the potential to significantly improve the prognosis for millions of individuals living with heart valve disease, particularly children and young adults who would otherwise undergo frequent open heart surgeries or lifelong medication.
The company's dedication to advancing this field is evident in its extensive patent portfolio, consisting of three issued utility patents and multiple additional patent applications, all of which have secured exclusive licensing rights. Aptus Bioreactors also offers bench-top equipment that effectively re-creates cardiovascular conditions experienced by heart valves, addressing a critical gap in the ability of researchers to develop and test such innovative products.
With a focus on scalability, the independently-controlled systems not only facilitate the development of tissue-engineered heart valve replacements but also hold the potential to replace early-stage animal studies and provide a promising manufacturing solution for various cardiovascular devices.
While specific investment details are not available at this time, the potential for disruption and societal impact positions Aptus Bioreactors as a compelling opportunity for venture capitalists seeking to invest in groundbreaking biotechnology and healthcare ventures.
